Leqvio (Inclisiran)

Inclisiran is a small interfering RNA that targets the messenger RNA for PCSK9 in liver cells. By degrading this mRNA, it reduces the production of the PCSK9 protein, which normally promotes degradation of LDL receptors. Fewer PCSK9 molecules allow more LDL receptors to recycle to the cell surface, increasing clearance of LDL‑C from the bloodstream.

The dosing regimen for Leqvio is determined by the prescribing clinician based on the patient’s clinical profile and local guidelines. Typically, a single subcutaneous injection is administered at the start of therapy, followed by a second dose three months later, and then maintenance doses every six months, but the exact schedule must be confirmed by the prescriber.

Safety data for Inclisiran in pregnant or lactating women are limited, and the product is classified as having an unknown pregnancy category. Consequently, Leqvio should be avoided during pregnancy and breastfeeding unless the potential benefit justifies the potential risk, and the decision should be made by a qualified healthcare professional.

To request Leqvio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling where required—and assistance with import documentation.

Leqvio (inclisiran) is a siRNA‑based PCSK9 inhibitor, whereas agents such as evolocumab and alirocumab are monoclonal antibodies. All lower LDL‑C by reducing PCSK9 activity, but Leqvio’s dosing interval is longer (initial dose, 3‑month follow‑up, then every six months), potentially improving adherence compared with bi‑weekly or monthly antibody injections.

Leqvio must be stored refrigerated at 2 °C to 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temporary exposure to higher temperatures occurs, discard the product as potency may be compromised.

Leqvio is given as a subcutaneous injection into the abdomen, thigh, or upper arm by a qualified healthcare professional. The injection is performed using a pre‑filled syringe or autoinjector, following the dosing schedule prescribed by the clinician, typically beginning with a loading dose, a second dose at three months, and then maintenance doses every six months.

The most serious adverse events reported with Leqvio include severe hypersensitivity reactions such as anaphylaxis or angioedema, significant elevations in liver enzymes (ALT/AST), and rare cardiovascular events like myocardial infarction or stroke. Patients should be monitored for these reactions, and any signs of severe allergy or liver dysfunction require immediate medical evaluation.

Leqvio is contraindicated in individuals with known hypersensitivity to inclisiran or any excipients in the formulation. It should also be avoided in pregnant or breastfeeding women, patients with severe active liver disease, and those who have experienced serious adverse reactions to prior PCSK9‑targeted therapies. Clinicians must assess each patient’s medical history before initiating treatment.